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Introduction: ZD6474 (vandetanib) is an orally available inhibitor
of vascular endothelial growth factor receptor, epidermal growth
factor receptor, and RET receptor tyrosine kinase activity. This
study assessed the safety and tolerability of escalating doses of
ZD6474 in Japanese patients with solid, malignant tumors.
Methods: Adult patients with solid tumors refractory to standard
therapy received a once-daily oral dose of ZD6474 (100–400 mg) in
28-day cycles, until disease progression or unacceptable toxicity was
observed.
Results: Eighteen patients were treated at doses of 100 mg (n  3),
200 mg (n 6), 300 mg (n 6), and 400 mg (n 3). Dose-limiting
toxicities at the completion of cycle 2 were hypertension (n  3),
diarrhea (n  1), headache (n  1), toxic skin eruption (n  1), and
alanine aminotransferase increase (n  1). A dose of 400 mg/day
was considered to exceed the maximum tolerated dose (MTD).
Toxicities were manageable with dose interruption and/or reduction.
Objective tumor response was observed in four of nine patients with
non-small cell lung cancer (NSCLC) at doses of either 200 or 300
mg. Terminal half-life was about 90–115 hours. Plasma trough
concentrations achieved steady-state conditions after approximately
1 month of daily dosing.
Conclusions: It was concluded that a dose of 400 mg/day was
considered to exceed the MTD, and doses for phase II study were
thought to be not more than 300 mg/day. The objective response
observed in some NSCLC patients is encouraging for further studies
in this tumor type.
Key Words: Phase I study, ZD6474, Vandetanib, Non-small cell
lung cancer
(J Thorac Oncol. 2006;1: 1002–1009)
Vascular endothelial growth factor (VEGF) is a potentstimulator of angiogenesis and plays an essential role in
the formation and maintenance of the vasculature by activat-
ing protease expression, endothelial cell proliferation and
migration, and capillary vessel formation.1–4 Enhanced secre-
tion of VEGF from tumor tissue induces vascular permeabil-
ity and results in the development of a network of highly
permeable, immature vessels that are characteristic of patho-
logical angiogenesis.5 Although VEGF binds to VEGFR-1
(Flt-1) and VEGFR-2 (KDR or Flk-1) on vascular endothelial
cells, activation of VEGFR-2 alone is sufficient to stimulate
VEGF-mediated angiogenesis.6 Pathological angiogenesis is
necessary for the progression of solid, malignant tumors,7 and
inhibition of VEGF-dependent signaling has been identified
as a key antiangiogenic strategy.8,9 The clinical value of
inhibiting VEGF signaling in colon cancer,10 non-small cell
lung cancer (NSCLC),11 and breast cancer12 has been con-
firmed with bevacizumab, an anti-VEGF antibody.
Epidermal growth factor receptor (EGFR)-dependent
signaling is an important pathway contributing to the growth
and metastasis of tumor cells, and aberrant EGFR tyrosine
kinase activity has been reported in a number of human
tumors.13,14 One consequence of upregulated EGFR tyrosine
kinase activity is increased expression of proangiogenic fac-
tors, including VEGF,15,16 which may lead to possible para-
crine and autocrine stimulation of angiogenesis.
ZD6474 (vandetanib; ZACTIMA) is a novel inhibitor
of VEGFR, EGFR, and RET tyrosine kinase activity.17–20 As
such, ZD6474 has the potential to inhibit two key pathways in
tumor growth: VEGF-dependent tumor angiogenesis, and
EGFR- and RET-dependent tumor cell proliferation and sur-
vival. Indeed, preclinical evaluation of ZD6474 has demon-
strated potent inhibition of VEGF-dependent signaling and
angiogenesis in vivo, as well as dose-dependent inhibition of
tumor growth, including profound regression in established
PC-3 prostate tumors. More recently, the results of a phase I
study of ZD6474 conducted in the United States and Austra-
lia showed that once-daily continuous oral dosing was gen-
erally well tolerated in patients with advanced tumors.21
We report the results of a phase I, open-label, nonran-
domized, multicenter clinical study of ZD6474 in Japanese
patients with advanced solid tumors. The primary objective
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of the study was to assess the safety and tolerability of
escalating oral doses of ZD6474, with the aim of establishing
the maximum tolerated dose (MTD) and the recommended
doses for further phase II study assessment. Additional ob-
jectives included evaluation of antitumor activity and assess-
ment of single- and multiple-dose pharmacokinetics.
PATIENTS AND METHODS
Patients
Adult patients between 20 and 74 years of age with
solid, malignant tumors refractory to standard therapies, or
for which no appropriate therapy exists, were eligible for
inclusion. Patients were required to have a life expectancy
3 months and a World Health Organization performance
status of 0 or 1. The main exclusion criteria were significant
cardiac, hematopoietic, hepatic or renal dysfunction; severe
complications (including active double cancers); any gastro-
intestinal disease that would affect drug bioavailability;
poorly controlled hypertension; CNS tumors and metastases;
systemic anticancer therapy or radiotherapy within the pre-
vious 4 weeks; unresolved adverse effects from prior anti-
cancer therapy or radiotherapy; and incomplete recovery
from prior surgery. All patients provided written informed
consent. The trial was approved by the ethics committee of
institutional review board and was conducted in accordance
with the Declaration of Helsinki and guidelines for good
clinical practice.
Study Design
This was an open-label, nonrandomized, multicenter
dose-escalation study. Patients received a single oral dose of
ZD6474 (100, 200, 300, or 400 mg), which was followed by
a 7-day observation period (cycle 0; Figure 1). On day 8,
patients started a once-daily ZD6474 dosing regimen at the
same dose as they had received in cycle 0 for a total of 28
days (cycle 1). Further 28-day treatment cycles were repeated
at the same dose. A dose-limiting toxicity (DLT) was defined
as any toxicity of at least grade 3 according to common
toxicity criteria (CTC version 2.0) that was related to ZD6474
treatment, or grade 2 diarrhea daily for 7 days or grade 3
diarrhea despite maximum antidiarrheal support; grade 2
skin toxicity for7 days that affected the patient’s subjective
well-being and required cessation of treatment, despite sup-
portive care; and QT or corrected QT (QTc) prolongation
490 msec, or a rise of 60 msec from baseline QT or QTc
to 460 msec. QTc values were obtained using Bazett’s22
method of correction.
The initial dose of ZD6474 was set at 100 mg/day,
based on the minimum toxic effect dose in rats as well as
safety data from U.S./Australian phase I study. Dose escala-
tion was performed when a minimum of three patients per
dose level had completed cycle 1 (28 days) without experi-
encing a DLT. The MTD was defined as the dose of drug at
which 33.3% of patients experienced a DLT during cycle 1
that was not controlled with symptomatic therapy. Once the
MTD was established, three or more additional patients were
enrolled at the two highest dose levels below the MTD. This
was to further characterize the safety, tolerability, and bio-
logical activity of ZD6474.
Assessment of Safety and Tolerability
The primary objective was to assess the safety and
tolerability of escalating oral doses of ZD6474. After full
physical examination at enrollment, adverse events (AEs)
were recorded at each scheduled study visit.
Electrocardiograms (ECGs) were recorded at the
screening visit, on days 1 (baseline) and 2 of cycle 0, and
three times per week up to day 21 of cycle 1. If no prolon-
gation of QT or QTc occurred, ECGs were performed weekly
up to day 14 of cycle 2, every 2 weeks until the end of cycle
3 and monthly during subsequent cycles; and 29 days after
the last dose. Vital signs (blood pressure, pulse rate, and body
temperature) were measured before and 2, 4, 6, 8, and 10
hours after the drug administration on day 1, and then every
24 hours until day 7 of cycle 0; every 24 hours until day 15
of cycle 1; weekly thereafter until the end of cycle 2; once
every 2 weeks during subsequent cycles; and at withdrawal.
Blood chemistry and hematological assessments were
performed at the screening visit; predose of cycle 0; predose
and on days 8, 15, 22, and 29 of cycles 1 and 2; every 2 weeks
(days 15 and 29) during subsequent cycles; at withdrawal;
and on days 15 and 29 after the last dose. Electrolytes were
measured weekly for patients who experienced diarrhea or
vomiting. Urinalysis was performed at the screening visit; on
day 2 of cycle 0; on days 15 and 29 of cycle 1; on day 29
during subsequent cycles; at withdrawal; and on days 15 and
29 after the last dose.
Pharmacokinetic Assessment
The pharmacokinetic profile of ZD6474 was assessed
after both single and multiple dosing. During cycle 0, blood
FIGURE 1. Study design. PD, progressive
disease; DLT, dose-limiting toxicity.
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samples were collected before and 1, 2, 4, 6, 8, 10, 24, 48, 96,
120, and 144 hours after administration. During cycle 1,
blood samples were collected before administration on days
1, 8, 14, 22, and 28 and 2, 4, 6, 8, 10, and 24 hours after
administration on day 28. Samples were also collected before
administration on days 15 and 29 of cycles 2 and 3, before
administration on day 29 of subsequent cycles, and at with-
drawal. Plasma concentrations of ZD6474 were determined
using high-performance liquid chromatography with mass
spectrometry (LC-MS/MS). Cmax and tmax were determined
by visual inspection of the plasma concentration time data for
ZD6474 for each patient on each sampling occasion. Where
there were adequate data, ZD6474 plasma elimination half-
life (t½) was determined by log-linear regression of those
points considered to constitute the terminal phase. The area
under the plasma concentration time curve (AUC0–t) was
calculated using the linear trapezoidal rule. The accumulation
ratio based on AUC0–24 was calculated by ratio of AUC0–24
after 28-day multiple doses to AUC0–24 after a single dose.
Assessment of Tumor Response
Tumor response was evaluated using the Response
Evaluation Criteria in Solid Tumors (RECIST) guidelines23 at
the end of each treatment cycle. Baseline tumor assessments
were performed before the start of single dosing.
Statistical Analyses
All analyses were descriptive, with no formal statistical
analysis performed on the data from this study. AEs were
coded according to both the Medical Dictionary for Regula-




All 18 patients (11 male, 7 female) enrolled in the study
received ZD6474 treatment and were evaluable for safety,
efficacy, and pharmacokinetics. Initially, three patients each
were enrolled in the 100-, 200-, 300-, and 400 mg groups.
Subsequently, three additional patients were enrolled in the
200- and 300-mg groups. Overall, 3, 6, 6, and 3 patients
received ZD6474 100, 200, 300, and 400 mg, respectively.
The overall patient population profile is summarized in
Table 1. Median duration of ZD6474 treatment was 56.5
(22–556) days. The median duration (range) of each dose
group was 43.0 (30–45), 191.5 (29–556), 76.5 (25–124), and
37.0 (22–42) days in the 100-, 200-, 300-, and 400-mg
groups, respectively. The reasons for discontinuation were
radiological or clinical disease progression (n  12), AEs
(n  5), or disease-related postrenal failure (n  1).
Safety and Tolerability
All patients experienced at least one AE. Drug-related
AEs by CTC grade with an incidence of at least 20% of the
overall population are summarized in Table 2. The most
common drug-related AEs were rash (n  13), prolongation
of QTc interval (n  12), diarrhea (n  11), and proteinuria
(n  11). There were various types of rash such as acne,
dermatitis acneform, macular rash, maculopapular rash, pus-
tular rash, erythema, folliculitis, photosensitivity rash, follic-
ular rash, and skin eruption. Although there were no skin
disorders of grade 3 or 4 severity, one patient in the 300-mg
group developed grade 2 toxic skin eruption, which persisted
for 7 days despite medical treatments and local supportive
care. Because of this, the event was defined as DLT, and the
study treatment was discontinued.












Male/female 1/2 5/1 3/3 2/1 11/7
Median age, yr (range) 50 (44–67) 52.5 (41–72) 55.5 (31–68) 53 (40–62) 52 (31–72)
Performance status (0/1) 1/2 2/4 2/4 1/2 6/12
Primary tumor diagnosis (n)
NSCLC 1 3 3 2 9
Colorectal 1 1 1 1 4
Breast 0 1 0 0 1
Stomach 0 0 1 0 1
Other* 1 1 1 0 3
Number of prior cancer treatments† 3 6 6 3 18
Chemotherapy 3 6 5 3 17
Radiotherapy 1 1 3 1 6
Median duration of ZD6474 treatment, days (range) 43 (30–45) 191.5 (29–556) 76.5 (25–124) 37.0 (22–42) 56.5 (22–556)
*Various other tumor types.
†Includes surgery, chemotherapy, immunotherapy, hormonal therapy, and radiotherapy.
NSCLC, non-small cell lung cancer.
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All episodes of QT or QTc prolongation in this study
were asymptomatic and considered by the investigator to be
drug related. QTc prolongation necessitated dose interruption
in 7 of 12 patients, 6 of whom were able to resume ZD6474
treatment at a reduced dose. The remaining patient was
discontinued from the study after experiencing QTc prolon-
gation, despite resuming treatment at a reduced dose.
No grade 4 drug related AE was observed. Seven
patients experienced grade 3 drug-related AEs. The most
common grade 3 drug-related AE was hypertension. One
patient who had grade 3 hypertension in the 300-mg group
was urgently hospitalized for hypertension and headache
(both of grade 3) at 6 weeks after the start of multiple dosing.
The symptoms were relieved 3 weeks after dose interruption,
and the treatment with ZD6474 was resumed at a reduced
dose of 150 mg/day. Eight patients had dose interruption, and
five patients discontinued study treatment because of AEs.
Drug-related AEs that led to treatment discontinuation were
increased alanine aminotransferase, fatigue, hypoacusis, pro-
longed QTc interval, and toxic skin eruption (all n  1).
Mean arterial blood pressure increased in most patients
after multiple dosing with ZD6474. Hypertension or in-
creased blood pressure was reported as an AE in eight
patients (n  4, grade 1 or 2; n  4, grade 3). In five of these
eight patients, the AE required treatment with standard anti-
hypertensive medication (primarily Ca2-channel blockers or
ACE inhibitors). There were no clinically relevant hemato-
logical toxicities. Elevations of ALT, asparate aminotransfer-
ase, and alkalinephosphatase reported as AE were in 6, 6, and
5 patients, respectively. Urinalysis revealed raised -N-
acetyl-D-glucosaminidase (n  6) and proteinuria (n  11),
but all of these events were classified as CTC grade 1.
Elevations of serum creatinine level were observed in three
patients.
In total, five patients experienced drug-related DLTs up
to the completion of cycle 2 (Table 3). Because 33.3% of
patients in the 400-mg cohort developed a DLT during cycle
1, 400 mg was considered to exceed the MTD.
Pharmacokinetic Evaluation
Pharmacokinetic parameters following a single oral
dose and multiple oral doses of ZD6474 (100–400 mg) are
shown in Tables 4. Plasma concentration of ZD6474 de-
creased biphasically (Figure 2A). The terminal half-life
seemed to be independent of the dose and was estimated to be
approximately 100 hours; this may be underestimated be-
cause up to 40% of the AUC was extrapolated. Mean plasma
trough concentrations of ZD6474 during continuous oral
dosing indicate that steady state is achieved after about 1
month of treatment (Figure 2B). Based on the AUC0–24 h on
days 1 and 28, exposure to ZD6474 increased approximately
sixfold after multiple dosing compared with a single dose.
The relationship between AUC and dose after a single dose
and 28-day multiple dosing was shown in Figure 3A and B,
respectively. Exposure to ZD6474 as assessed by AUC after
a single oral dose seemed to show an increase with dose.
There was an approximately threefold interindividual vari-
ability in AUC at the same dose level.













G1/2 G3 G1/2 G3 G1/2 G3 G1/2 G3
Rash (NOS) 1 0 6 0 4 0 2 0 13
Electrocardiogram QT corrected interval prolonged 2 0 4 0 4 0 2 0 12
Diarrhea (NOS) 1 0 4 0 3 1 2 0 11
Proteinuria 1 0 4 0 4 0 2 0 11
Fatigue 1 0 1 1 2 0 3 0 8
Hypertension† (NOS) 0 0 1 2 1 1 1 1 7
Blood lactate dehydrogenase increased 0 0 4 0 1 0 2 0 7
ALT increased 0 0 3 0 1 0 1 1 6
Anorexia 1 0 2 0 2 0 1 0 6
AST increased 0 0 3 0 1 0 2 0 6
-N-acetyl-D-glucosaminidase increased 0 0 4 0 1 0 1 0 6
Hematuria 1 0 2 0 0 0 2 0 5
Headache 0 0 1 0 1 1 2 0 5
Lymphopenia 0 1 2 0 1 0 1 0 5
Blood alkalinephosphatase 0 0 3 0 1 0 1 0 5
Nausea 0 0 1 0 2 0 1 0 4
*Medical dictionary for regulatory activities (MedDRA) preferred term.
†Includes one patient with an adverse event reported as blood pressure increased.
CTC, common toxicity criteria; NOS, not otherwise specified; ALT, alanine aminotransferase; AST, asparate aminotransferase.
No grade 4 drug-related adverse events were reported.
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Tumor Response
Tumor responses were evaluated in 18 patients. No
complete response was observed, but four patients achieved a
confirmed partial response (three patients in the 200-mg
group and one patient in the 300-mg group), all of whom had
NSCLC with adenocarcinoma. Prior cancer treatments in
these four patients included chemotherapy (n  4), surgery
(n  2), and radiotherapy (n  2). Each of the responders
experienced dose interruptions/reduction because of AEs, but
their responses were maintained at a reduced dose of 100 or
200 mg/day; the individual time to onset of response was 36,
64, 70, and 103 days, with a respective duration of response
of 90, 230, 246, and 438 days (Table 5). Three of the four
responders subsequently discontinued treatment because of
AEs. Representative CT scans from two responders are
shown in Figure 4.
DISCUSSION
In this phase I dose-escalation study, once-daily oral
dosing with ZD6474 was generally well tolerated at doses up
to and including 300 mg in Japanese patients with solid,
malignant tumors. Pharmacokinetic analyses confirmed that
once-daily oral dosing was appropriate for ZD6474, which
had an estimated half-life of approximately 5 days. Notably,
partial tumor response was observed in four out of nine
patients with refractory NSCLC.
The most common drug-related AEs were rash, QTc
prolongation, diarrhea, and proteinuria. QTc prolongation
was reported at all doses studied, with no clear evidence of
dose dependency. All patients with QTc prolongation were
asymptomatic, and most did not require withdrawal of
ZD6474 treatment. QTc prolongation was reversible and can
be managed through dose interruption or dose reduction.
TABLE 4. Pharmacokinetic Parameters of ZD6474 After a Single Dose (Cycle 0) and
After Multiple Dosing for 28 Days (Cycle 1)










Mean Cmax, ng/mL (SD) 103 (42) 186 (92) 392 (198) 447 (240)
Median tmax, hr (range) 6 (4–6) 4 (4–6) 5 (4–8) 6 (2–6)
Mean AUC0–24 h, g·hr/ml (SD) 1.5 (0.5) 2.8 (1.5) 5.6 (2.5) 6.7 (3.0)
Mean AUC, g·hr /ml (SD) 10.1 (3.5) 16.8 (6.9) 29.4 (11.8) 32.1 (4.7)
Mean t½, hr (SD) 115 (46) 101 (14) 90 (14) 114 (45)









Mean Cmax, ng/mL (SD) 1200 (583) 922 (259) 1580 (302) 2050
Median tmax, hr (range) 4 (4–6) 6 (4–10) 6 (6–6) 4
Mean AUC0–24h, g·hr/ ml (SD) 20.5 (5.0) 18.3 (5.7) 29.9 (4.6) 44.6
Accumulation index* (SD) 14.2 (1.8) 6.2 (1.9) 5.3 (1.2) 6.5
*Day 28 AUC0–24 h/day 1 AUC0–24 h.
AUC, area under the curve to infinity; AUC0–24 h, area under the curve to 24 hr; Cmax, maximum concentration; SD,
standard deviation; tmax, time to maximum concentration; t½, terminal half-life.
TABLE 3. Drug-Related Dose-Limiting Toxicity (DLT) at the Completion of Cycle 2




Cycle 1 Cycle 2
100 3 0/3 None None
200 3 0/3 None None
3 1/3 Hypertension None
(additional cohort)
300 3 1/3 None Hypertension, diarrhea, headache†
3 1/3 None Toxic skin eruption
(additional cohort)
400 3 2/3 Hypertension Alanine aminotransferase increased
*All DLTs were CTC grade 3 except for grade 2 toxic skin eruption.
†Observed in the same patient.
CTC, common toxicity criteria; ALT, alanine aminotransferase.
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There were some T-wave and U-wave changes in ECG,
but there was no consequent arrhythmia finding in ECG.
However, ECG monitoring should continue in future clini-
cal trials.
Hypertension was also reported as a drug-related AE in
seven patients, but no patients withdrew from the study as a
result of hypertension, and all cases were controllable with
dose adjustment or appropriate drug therapy. Rash and hy-
pertension were also reported as relatively common AEs in a
larger phase I study of ZD6474, which was conducted in the
United States and Australia.21 These events could be indica-
tive of target inhibition by ZD6474. Also, because synthesis
TABLE 5. Summary of Partial Responders
Patient No. Age (yr) Sex
Initial ZD6474






301 72 M 200 200¡100 mg (day 28) 64 230
304 54 M 200 200¡100 mg (day 42) 103 438
305 41 M 200 200¡100 mg (day 276) 70 246
406 50 F 300 300¡200 mg (day 79) 36 90
aDose reduction was attributable to AEs: QT/QTc prolongation (#301); hypertension (#304); rash (#305); toxic skin eruption (#406).
bDose discontinuation was attributable to: hypoacusis (#301); disease progression (#304); fatigue (#305); toxic skin eruption (#406).
FIGURE 2. (A) Mean (SD) plasma concentration of ZD6474 after a single oral dose. (B) Mean (SD) plasma trough con-
centration of ZD6474 during continuous oral dosing for 28 days (cycle 1).
FIGURE 3. (A) Relationship between AUC and dose after a single oral dose of ZD6474. (B) Relationship between AUC0–24
and dose after 28-day multiple doses of ZD6474. AUC, area under the curve from zero to infinity; AUC, area under the curve
from 0 to 24 hours.
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of the vasodilator nitric oxide is downstream of VEGF-
induced angiogenesis signaling,24 inhibition of VEGFR-de-
pendent signaling by ZD6474 may decrease nitric oxide
production and lead to hypertension. Hypertension and ele-
vated ALT levels were reported as DLTs in the 400-mg dose
group during the period up to completion of cycle 2. As a
result, this dose was considered to exceed the MTD.
Rash may be a consequence of EGFR inhibition, with
the consideration that dose-dependent development of rash
was reported in studies of other EGFR inhibitors, erlotinib25
and gefitinib.26,27 Because different types of rash, including
erythema and photosensitivity, were observed in this study, it
seems that the rash induced by ZD6474 may be more varied
and systematic than was reported with those EGFR inhibitors.
Pharmacokinetic assessment in this study has con-
firmed that ZD6474 offers a convenient once-daily oral dos-
ing schedule that is sufficient to achieve steady-state expo-
sure. In this respect, the pharmacokinetic characteristics of
ZD6474 in this Japanese study did not differ from those
obtained in the U.S./Australian study.21
Although this study was primarily designed to assess
safety and tolerability, secondary assessment of efficacy re-
vealed that four out of nine patients with NSCLC exhibited a
partial response to ZD6474 treatment at initial daily doses of
200 mg (n  3) and 300 mg (n  1). It is worth noting that
partial tumor response was maintained in these patients
(range 90–438 days) despite subsequent reductions in daily
dose. This finding has prompted evaluation of ZD6474 in
patients with NSCLC in phase II studies.28–30 Although
EGFR mutational status was not determined for any patients
in the current study, a recent preclinical study showed that the
antiproliferative effects of ZD6474 were augmented in an
NSCLC cell line harboring EGFR containing a small in-
frame deletion mutation.31 Characteristics predicting re-
sponse to gefitinib such as female gender, adenocarcinoma,
nonsmoking status, Asian ethnicity, and EGFR mutations
should be investigated in future studies.
Multiple signaling pathways contribute to tumor-re-
lated angiogenesis and tumor growth and metastasis. As such,
novel therapies that target a single molecule or biochemical
pathway may have less clinical efficacy than agents with
more than one mode of action. Because ZD6474 is a selective
inhibitor of VEGFR-2 and EGFR tyrosine kinase activity,
this agent may be particularly beneficial in tumor types that
display aberrant activity of both signaling pathways. How-
ever, the relative contribution of VEGFR-2 and EGFR ty-
rosine kinase inhibition to the clinical activity of ZD6474 in
specific tumor types, as well as to the toxicity profile of
ZD6474, remains to be determined.
In conclusion, these data indicate that ZD6474 at oral
doses up to 300 mg/day was tolerated in Japanese patients
with advanced tumors. A dose of 400 mg/day was considered
to exceed the MTD, and doses of 300 mg/day were con-
sidered appropriate for evaluation in a further phase II
study.29
Targeting multiple pathways in cancer may be neces-
sary to provide sustained clinical benefit to patients, and
ZD6474 has the potential to inhibit two key pathways in
tumor growth by targeting VEGFR-dependent tumor angio-
genesis and EGFR-dependent tumor cell proliferation and
survival. Phase III development of ZD6474 in NSCLC has
been initiated, and the clinical development program contin-
ues to investigate efficacy in other tumor types.
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FIGURE 4. Representative CT
scans before and after ZD6474
treatment in two NSCLC (adeno-
carcinoma) patients with partial
responses. Baseline scans were per-
formed within 4 weeks before the
first dose. Male, 72 years (#301),
initial ZD6474 dose  200 mg.
Female, 50 years (#406), initial
ZD6474 dose  300 mg.
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